Anti-VEGF injections are not only uncomfortable for your patients; they’re also very cost-prohibitive. Researchers are working to develop new means of treating wet AMD that will reduce the frequency of anti-VEGF injections while improving outcomes, especially for those that are or have become non-responsive to treatments.
Since every case is different and has its own complexities, there are no hard and fast rules to determine the best course of action for your patients. As new drugs and other forms of treatments are developed, ensuring you understand how they may be beneficial to your patients is critical. One of the best ways to reduce the frequency of anti-VEGF injections to date is by applying a combination of current treatments.
Some doctors can decrease the injection intervals by switching or alternating the medications used to dry the retina. One doctor in particular, who co-wrote the PRONTO study focusing on alternative dosing schedules, has found that many of his patients benefited from a dosing regimen that alternates between Avastin and Lucentis. While Lucentis is significantly more costly and chemically similar to Avastin, it tends to dry the retina faster, which can result in fewer doses. While follow-up appointments to monitor possible fluid buildup or return …